[1] Collins DA, Hawkey PM, Riley TV. Epidemiology of Clostridium difficile infection in Asia. Antimicrob Resist Infect Control , 2013, 2(1): 21.
[2] Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, Bergwerff AA, Dekker FW, Kuijper EJ. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis , 2008, 47(9): 1162-1170.
[3] Kelly CP, LaMont JT. Clostridium difficile -more difficult than ever. N Engl J Med , 2008, 359(18): 1932-1940.
[4] Huang HH, Wu S, Wang MG, Zhang YY, Fang H, Palmgren AC, Weintraub A, Nord CE. Molecular and clinical characteristics of Clostridium difficile infection in a University Hospital in Shanghai, China. Clin Infect Dis , 2008, 47(12): 1606-1608.
[5] 陈云波, 吴微珍, 鲁海峰, 杨介钻, 王保红, 孔海深, 李兰娟. 艰难梭菌相关性腹泻患者50例临床特征及其病原菌耐药性分析. 浙江医学, 2010, 32(11): 1632-1634, 1640.
[6] Wang P, Zhou YL, Wang ZQ, Xie S, Chen Y, Jiang B, Zhang T, Lin MY, LI RH, Tan JS. Identification of Clostridium difficile ribotype 027 for the first time in Mainland China. Infect Control Hosp Epidemiol , 2014, 35(1): 95-98.
[7] Owens RJ, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis , 2008, 46(Suppl 1): S19-S31.
[8] Tickler IA, Goering RV, Whitmore JD, Lynn ANW, Persing DH, Tenover FC. Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013. Antimicrob Agents Chemother , 2014, 58(7): 4214-4218.
[9] Lachowicz D, Pituch H, Obuch-Woszczatynski P. Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012. Anaerobe , 2014, 31: 37-41.
[10] Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol , 2013, 108(4): 478-498, 499.
[11] Peláez T, Alcalá L, Alonso R, Martín-López A, García-Arias V, Marín M, Bouza E. In vitro activity of ramoplanin against Clostridium difficile , including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother , 2005, 49(3): 1157-1159.
[12] Huang H, Fang H, Weintraub A, Nord CE. Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm. Clin Microbiol Infect , 2009, 15(12): 1170-1173.
[13] Huang HH, Weintraub A, Fang H, Wu S, Zhang YY, Nord CE. Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains. Anaerobe , 2010, 16(6): 633-635.
[14] Roberts S, Heffernan H, Al Anbuky N, Pope C, Paviour S, Camp T, Swager T. Molecular epidemiology and susceptibility profiles of Clostridium difficile in New Zealand, 2009. N Z Med J , 2011, 124(1332): 45-51.
[15] Tenover FC, Tickler IA, Persing DH. Antimicrobial-resistant strains of Clostridium difficile from North America. Antimicrob Agents Chemother , 2012, 56(6): 2929-2932.
[16] Liao CH, Ko WC, Lu JJ, Hsueh PR. Characterizations of clinical isolates of Clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. Antimicrob Agents Chemother , 2012, 56(7): 3943-3949.
[17] Kim J, Kang JO, Pai H, Choi TY. Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea. Int J Antimicrob Agents , 2012, 40(1): 24-29.
[18] Goudarzi M, Goudarzi H, Alebouyeh M, Azimi Rad M, Shayegan Mehr FS, Zali MR, Aslani MM. Antimicrobial susceptibility of Clostridium difficile clinical isolates in Iran. Iran Red Crescent Med J , 20
